 The study compares the cost consequences of biologic drugs for moderate to severe psoriasis from the perspective of the Spanish national health system using a decision tree with a two-year time horizon. Secukinium abmonotherapy was found to be the most efficient treatment option, having the lowest number needed to treat and cost per responder. This article was authored by Luis Pulic, Joan Natario, Alberto Jimenez Morales, and others.